小線源治療は、内部放射線療法としても知られ、放射線がその近くまたは隣に配置された線源を介して体内の癌性腫瘍に直接照射される放射線療法の一種です。 線源は、近くの健康な組織への害を最小限に抑えながら、癌細胞を標的とするガンマ線を放出します。腫瘍の重症度や損傷の程度に応じて、低線量率（LDR）または高線量率（HDR）で行われます。LDRでは小さな放射性シードを腫瘍内またはその周辺に永久的に埋め込むのに対し、HDRでは各セッションの終了時に放射性ソースを患者の体から除去します。
小線源治療は、子宮頸癌、皮膚癌、乳癌の治療に非常に有効であることが示されており、これが市場拡大の原動力となっています。さらに、微小な腫瘍に正確かつ局所的に放射線を照射できる高品質の小線源治療機器が利用できるようになったことで、患者や医療関係者の間でこの治療法の受け入れが進んでいます。
世界各地でメディカルツーリズムが盛んになっていることに加え、小線源治療の利点、費用対効果、手術や外部ビーム治療（EBT）と比較した場合の治癒率の高さについての知識が高まっていることが、業界の発展を後押ししています。
目次
Contents
1. Executive Summary
2. Global Brachytherapy Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Brachytherapy Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Brachytherapy Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. Global Brachytherapy Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, South Korea, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Middle East and Africa: (Saudi Arabia, South Africa and rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Latin America (Brazil, Mexico, Rest of South America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Technique: Market Share (2020-2030F)
12.2.1. High Dose Rate Brachytherapy Devices, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Low Dose Rate Brachytherapy Devices, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Application: Market Share (2020-2030F)
12.3.1. Gynecologic Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Prostate cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Breast cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Other cancers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By End-User: Market Share (2020-2030F)
12.4.1. Hospitals, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Clinics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Academic medical centers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.4. Clinical Laboratories, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. Company Profile
13.1. Argon Medical Devices
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Becton
13.3. Dickinson and Company
13.4. Carl Zeiss Meditec AG
13.5. Eckert & Ziegler BEBIG S.A.
13.6. Elekta AB, iCAD Inc.
13.7. Isoray Inc.
13.8. Theragenics Corporation
13.9. iMedX Information Services
13.10. Varian Medical Systems Inc.
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
